Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
24 Nov 2025 03:54 PM
RNS
Holding(s) in Company
24 Nov 2025 09:30 AM
RNS
Holding(s) in Company
20 Nov 2025 12:11 PM
RNS
Result of GM & Issue of Equity
13 Nov 2025 02:16 PM
RNS
Holding(s) in Company
10 Nov 2025 07:00 AM
RNS
Holding(s) in Company
04 Nov 2025 05:15 PM
RNS
Posting of Circular and Notice of General Meeting
04 Nov 2025 07:00 AM
RNS
Result of WRAP Retail Offer
30 Oct 2025 07:21 AM
RNS
WRAP Retail Offer for up to £300,000
30 Oct 2025 07:17 AM
RNS
Fundraising of up to £1,050,000
14 Oct 2025 07:00 AM
RNS
Inaphaea Commercial update
29 Sep 2025 07:00 AM
RNS
Half-year Report
18 Sep 2025 07:00 AM
RNS
Inaphaea Commercial Update
01 Sep 2025 07:00 AM
RNS
Cytolytix Commercial update
26 Aug 2025 07:00 AM
RNS
Commercial update
07 Aug 2025 10:51 AM
RNS
ValiRx Awarded Grant from Open University
05 Aug 2025 09:53 AM
RNS
Update on Evaluation Agreement with Stingray Bio
04 Aug 2025 07:00 AM
RNS
Licensing Agreement with Dominion Biotech Ltd
29 Jul 2025 07:00 AM
RNS
Collaboration Agreement with Voxcell BioInnovation
30 Jun 2025 03:48 PM
RNS
Result of AGM
20 Jun 2025 07:00 AM
RNS
Ambrose Exercise Option on VAL401
09 Jun 2025 10:57 AM
RNS
ValiRx Investor Webinar
06 Jun 2025 10:54 AM
RNS
Holding(s) in Company
06 Jun 2025 07:00 AM
RNS
Final Results & Notice of AGM
03 Jun 2025 07:00 AM
RNS
New Evaluation and Material Transfer Agreement
20 May 2025 01:25 PM
RNS
Holding(s) in Company
12 May 2025 07:00 AM
RNS
Inaphaea Deal Extension With Dominion
30 Apr 2025 07:00 AM
RNS
Commercial Update
03 Apr 2025 07:00 AM
RNS
Termination of Letter of Intent with TheoremRx
27 Mar 2025 07:00 AM
RNS
Directorate Changes and new Advisory Board
21 Mar 2025 11:07 AM
RNS
Director Disclosure Update
24 Feb 2025 07:00 AM
RNS
Conclusion of Evaluation Project
03 Feb 2025 07:00 AM
RNS
Inaphaea Evaluation and Commercial Use Agreement
30 Jan 2025 07:00 AM
RNS
Extension of Evaluation Agreement
29 Jan 2025 07:00 AM
RNS
New Evaluation and Option Agreement
15 Jan 2025 12:47 PM
RNS
Holding(s) in Company
15 Jan 2025 11:29 AM
RNS
Holding(s) in Company
14 Jan 2025 07:00 AM
RNS
Holding(s) in Company
09 Jan 2025 11:37 AM
RNS
Holding(s) in Company
09 Jan 2025 11:14 AM
RNS
Holding(s) in Company
08 Jan 2025 07:00 AM
RNS
Holding(s) in Company
02 Jan 2025 11:45 AM
RNS
Holding(s) in Company
31 Dec 2024 01:06 PM
RNS
Holding(s) in Company
31 Dec 2024 08:39 AM
RNS
Update on proposed sub-license of VAL201
30 Dec 2024 01:30 PM
RNS
Result of GM, Issue of Equity, Warrants and TVR
20 Dec 2024 07:00 AM
RNS
ValiRx launches new interactive investor website
10 Dec 2024 04:45 PM
RNS
Broker Offer Results & Director/PDMR Subscription
10 Dec 2024 03:03 PM
RNS
Posting of Circular and Notice of General Meeting
09 Dec 2024 07:00 AM
RNS
Conditional Fundraising & Launch of Broker Offer
22 Nov 2024 07:00 AM
RNS
Inaphaea award of HEIF Funding and PhD sponsorship
20 Nov 2024 07:00 AM
RNS
Update on proposed sub-license of VAL401

ValiRx is a fast-growing drug development company focused on identifying novel science with high potential for successful development into products that improve the lives of patients throughout treatment.

ValiRx share price listed on AIM in 2004 under the ticker VAL.

UK 100

Latest directors dealings